NEW YORK (GenomeWeb News) — Investment bank UBS today downgraded Cepheid’s stock to ‘neutral’ from ‘buy.’
 
Cepheid’s shares have risen 135 percent since the start of the year and reached a new 52-week high yesterday when they reached $20.29. Shares closed at $20.17 that day.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

In Nature this week: a Danish reference genome, and more.